AI-generated summary
This narrative review summarizes recent literature on pachychoroid spectrum diseases, focusing on pathophysiology, multimodal imaging, and treatment. The authors report that these disorders share choroidal vascular abnormalities and that central serous chorioretinopathy can progress to neovascular complications. They state that emerging treatments, including photobiomodulation, are under investigation but that current evidence does not support their routine clinical use.
- Who or what was studied
- Patients with pachychoroid spectrum disorders of the macula, including central serous chorioretinopathy and related neovascular conditions
- Limits stated in the abstract
- The abstract describes a narrative review without a stated count of included studies, and it notes that evidence for emerging therapies, including photobiomodulation, does not yet support routine use.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on mehdijournal.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Photobiomodulation, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.